SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing significant volatility and intense community debate as investors weigh strong financial results and aggressive growth targets against concerns over potential share offerings and broader software sector weakness. While many remain bullish on the company's AI-driven ad engine and cash flow, traders are actively discussing the stock's unpredictable price swings and high-stakes positioning ahead of upcoming catalyst events.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing intense volatility as investors weigh strong international growth and record revenue against concerns over brand momentum and competitive pressures ahead of its upcoming earnings report. The community is actively debating whether the recent share price slide near 52-week lows represents a deliberate institutional accumulation phase or a signal of fundamental weakness.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a major leadership overhaul, with new CEO and largest shareholder Kevin Tang taking the helm to drive strategy and prioritize shareholder value. The community is actively discussing the recent acquisition of Kezar Life Sciences and the potential for a strategic buyout, fueling optimistic speculation about the company's future direction.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending following a report positioning the company as a key supplier for AI infrastructure, specifically regarding co-packaged optics components for major tech industry players. The community is actively debating the sustainability of this price action, with many closely tracking significant spikes in trading volume and options activity ahead of key industry conferences.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing significant volatility and a sharp price correction as the market weighs competitive pressures from new AI agent technologies against the company's long-term infrastructure potential. Investors are actively debating whether this pullback represents a major fundamental breakdown or an overreaction that offers a strategic buying opportunity for the edge computing leader.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is heading into earnings with heightened volatility as investors weigh the company's path to profitability and potential AI-driven ad performance against concerns over executive leadership and stagnant North American user growth. While the community is divided between those betting on a turnaround through cost-cutting and potential buyout interest, others are actively preparing for typical post-earnings swings, debating if the stock is a deep-value opportunity or a long-term trap.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is seeing intense community focus due to significant volatility following a mixed earnings report that highlighted strong revenue growth alongside margin pressures. While some investors are concerned by operational losses and ongoing litigation, others are bullishly tracking the companys massive backlog and potential hyperscaler partnerships as key catalysts for a long-term turnaround.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending as investors weigh strong demand for its high-energy silicon anode battery technology against ongoing volatility driven by warrant redemption mechanics. Community discussion is focused on the company's expanding order backlog in the defense and electric mobility sectors, with many traders closely monitoring whether the share price can maintain the critical support levels required to trigger warrant exercises.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently trending due to a mix of investor frustration over executive performance and a strategic pivot to defensive, value-driven menu offerings intended to combat cooling consumer spending. The community is actively debating the company's long-term resilience as they navigate inflation concerns and aggressive operational changes.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant volatility as investors weigh strong fundamental performance and profitability against intense short-interest and broader macro uncertainty. While the community is actively discussing the stock's potential for a massive re-rating driven by its AI underwriting model and recent institutional wins, the price action remains heavily influenced by speculative trading and regional geopolitical concerns affecting the broader fintech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study

(RTTNews) - Alterity Therapeutics Limited (ATHE) on Monday said it received positive feedback from the U.S. Food and Drug Administration following a Type C meeting regarding its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA...

Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial

(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA...

Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor

(RTTNews) - Alterity Therapeutics Limited (ATHE), Wednesday announced the appointment of Daniel Claassen as Chief Medical Advisor, effective March 2026...

Shares of <a href="https://stocktwits.com/symbol/ATHE">Alterity Therapeutics</a> soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average.The clinical-stage biotech announced positive Phase 2 results for ATH434, its oral treatment for early-stage multiple system atrophy (MSA)— a rare neurodegenerative disease.Key findings from the 52-week trial:<ul style="list-style-type:square;"><li>50 mg dose: 48% reduction in clinical progression vs. placebo</li><li>75 mg dose: 29% reduction in clinical progression vs. placebo</li></ul>The 50 mg dose reduced iron accumulation in multiple system atrophy-affected brain regions, while the 75 mg dose specifically reduced iron buildup in the globus pallidus.CEO David Stamler said, “Currently, there are no approved treatments that slow the progression of MSA, and these results show ATH434’s targeted iron engagement may truly have a disease-modifying effect.”<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ATHE_sentiment_and_message_volume_Jan_30_premarket_df297a4b9a.png" alt="ATHE sentiment and message volume Jan 30 premarket.png" width="1318" height="324"><figcaption>ATHE sentiment and message volume Jan 30 premarket as of 9 am ET | source: Stocktwits</figcaption></figure>Stocktwits message volume for Alterity skyrocketed, hitting ‘extremely high’ levels ahead of Thursday’s&nbsp;opening bell, with sentiment hitting the highest reading in over a year.Some users predicted ATHE could more than triple, stabilizing around $10, while others reiterated their bullish stance on the drug’s market potential.<stembedurl>https://stocktwits.com/AshleySchaeffer_BMW/message/602113870</stembedurl><stembedurl>https://stocktwits.com/DaBullRunner/message/602113078</stembedurl>ATHE was among the top three trending tickers on Stocktwits early Thursday.&nbsp;Message volume around the stock on the platform has surged 700% over the past year, during which it has gained 46%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars

A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.  

Equity

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Ltd - ADR

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

ATHE
Alterity Therapeutics Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest ATHE News

ATHEAlterity Therapeutics Ltd - ADR